Pay in 4 interest-free payments of $6.08 Learn more
Ships within 48 hours · Estimated delivery Oct 1 - Oct 6
2 In the REIMAGINE 3 trial, the most commonly reported AEs were GI-related, occurring in 51/90 (57%) participants in the CagriSema 2.4 mg/2.4 mg group, 42/93 (45%) participants in the CagriSema 1 mg/1 mg group, and 21/91 (23%) participants in the placebo group
Nazarian leads our team in utilizing evidence-based approaches that prioritize your long-term health and wellness
CagriSema FDA approval timeline Novo Nordisk submitted the New Drug Application (NDA) to the FDA on December 18, 2025 , for chronic weight management in adults with obesity or overweight with a weight-related comorbidity
GLP-1 Peptide Therapy For Weight Loss GLP-1 (Glucagon-Like Peptide-1) is a naturally occurring hormone in the body that plays a critical role in regulating glucose metabolism and appetite
US$ 21.71
US$ 25.78
US$ 26.57
US$ 29.41
US$ 21.61
US$ 24.71
US$ 24.59
US$ 27.68
US$ 27.71
